COPBLAM III

infusional combination chemotherapy for diffuse large-cell lymphoma

D. B. Boyd, M. Coleman, S. W. Papish, A. Topilow, S. K. Kopel, B. Bernhardt, J. C. Files, S. Schwartz, M. Gaynor, D. McDermott, A. M. Reisman, B. L. Coleman

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

COPBLAM III, a polychemotherapy regimen consisting of cyclophosphamide, infusional vincristine, prednisone, infusional bleomycin, doxorubicin, and procarbazine, was administered to 51 patients with diffuse large-cell lymphoma. Ninety-six percent of patients age 60 or younger achieved a complete response (CR); none have relapsed. Overall, 88% of patients are alive and well and potentially in the survival plateau. For patients > 60 years, CR was obtained in 73%, with 42% potentially in the survival plateau, the difference resulting in part from four relapses, three toxic deaths, and one presumed unrelated death. These results in the elderly were paralleled by a relatively reduced ability to tolerate therapy. Toxicity was primarily pulmonary, occurring in 39% of patients, two of whom died. With an overall CR rate of 84%, of which 92% are sustained at a median follow-up of 40 months, COPBLAM III represents a highly effective treatment in a sizeable cohort of patients.

Original languageEnglish (US)
Pages (from-to)425-433
Number of pages9
JournalJournal of Clinical Oncology
Volume6
Issue number3
DOIs
StatePublished - Jan 1 1988

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Combination Drug Therapy
Procarbazine
Survival
Poisons
Bleomycin
Vincristine
Prednisone
Doxorubicin
Cyclophosphamide
Recurrence
Lung
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Boyd, D. B., Coleman, M., Papish, S. W., Topilow, A., Kopel, S. K., Bernhardt, B., ... Coleman, B. L. (1988). COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma. Journal of Clinical Oncology, 6(3), 425-433. https://doi.org/10.1200/JCO.1988.6.3.425
Boyd, D. B. ; Coleman, M. ; Papish, S. W. ; Topilow, A. ; Kopel, S. K. ; Bernhardt, B. ; Files, J. C. ; Schwartz, S. ; Gaynor, M. ; McDermott, D. ; Reisman, A. M. ; Coleman, B. L. / COPBLAM III : infusional combination chemotherapy for diffuse large-cell lymphoma. In: Journal of Clinical Oncology. 1988 ; Vol. 6, No. 3. pp. 425-433.
@article{7c8dedb6c40240209eae6d69d876b2d7,
title = "COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma",
abstract = "COPBLAM III, a polychemotherapy regimen consisting of cyclophosphamide, infusional vincristine, prednisone, infusional bleomycin, doxorubicin, and procarbazine, was administered to 51 patients with diffuse large-cell lymphoma. Ninety-six percent of patients age 60 or younger achieved a complete response (CR); none have relapsed. Overall, 88{\%} of patients are alive and well and potentially in the survival plateau. For patients > 60 years, CR was obtained in 73{\%}, with 42{\%} potentially in the survival plateau, the difference resulting in part from four relapses, three toxic deaths, and one presumed unrelated death. These results in the elderly were paralleled by a relatively reduced ability to tolerate therapy. Toxicity was primarily pulmonary, occurring in 39{\%} of patients, two of whom died. With an overall CR rate of 84{\%}, of which 92{\%} are sustained at a median follow-up of 40 months, COPBLAM III represents a highly effective treatment in a sizeable cohort of patients.",
author = "Boyd, {D. B.} and M. Coleman and Papish, {S. W.} and A. Topilow and Kopel, {S. K.} and B. Bernhardt and Files, {J. C.} and S. Schwartz and M. Gaynor and D. McDermott and Reisman, {A. M.} and Coleman, {B. L.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1200/JCO.1988.6.3.425",
language = "English (US)",
volume = "6",
pages = "425--433",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

Boyd, DB, Coleman, M, Papish, SW, Topilow, A, Kopel, SK, Bernhardt, B, Files, JC, Schwartz, S, Gaynor, M, McDermott, D, Reisman, AM & Coleman, BL 1988, 'COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma', Journal of Clinical Oncology, vol. 6, no. 3, pp. 425-433. https://doi.org/10.1200/JCO.1988.6.3.425

COPBLAM III : infusional combination chemotherapy for diffuse large-cell lymphoma. / Boyd, D. B.; Coleman, M.; Papish, S. W.; Topilow, A.; Kopel, S. K.; Bernhardt, B.; Files, J. C.; Schwartz, S.; Gaynor, M.; McDermott, D.; Reisman, A. M.; Coleman, B. L.

In: Journal of Clinical Oncology, Vol. 6, No. 3, 01.01.1988, p. 425-433.

Research output: Contribution to journalArticle

TY - JOUR

T1 - COPBLAM III

T2 - infusional combination chemotherapy for diffuse large-cell lymphoma

AU - Boyd, D. B.

AU - Coleman, M.

AU - Papish, S. W.

AU - Topilow, A.

AU - Kopel, S. K.

AU - Bernhardt, B.

AU - Files, J. C.

AU - Schwartz, S.

AU - Gaynor, M.

AU - McDermott, D.

AU - Reisman, A. M.

AU - Coleman, B. L.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - COPBLAM III, a polychemotherapy regimen consisting of cyclophosphamide, infusional vincristine, prednisone, infusional bleomycin, doxorubicin, and procarbazine, was administered to 51 patients with diffuse large-cell lymphoma. Ninety-six percent of patients age 60 or younger achieved a complete response (CR); none have relapsed. Overall, 88% of patients are alive and well and potentially in the survival plateau. For patients > 60 years, CR was obtained in 73%, with 42% potentially in the survival plateau, the difference resulting in part from four relapses, three toxic deaths, and one presumed unrelated death. These results in the elderly were paralleled by a relatively reduced ability to tolerate therapy. Toxicity was primarily pulmonary, occurring in 39% of patients, two of whom died. With an overall CR rate of 84%, of which 92% are sustained at a median follow-up of 40 months, COPBLAM III represents a highly effective treatment in a sizeable cohort of patients.

AB - COPBLAM III, a polychemotherapy regimen consisting of cyclophosphamide, infusional vincristine, prednisone, infusional bleomycin, doxorubicin, and procarbazine, was administered to 51 patients with diffuse large-cell lymphoma. Ninety-six percent of patients age 60 or younger achieved a complete response (CR); none have relapsed. Overall, 88% of patients are alive and well and potentially in the survival plateau. For patients > 60 years, CR was obtained in 73%, with 42% potentially in the survival plateau, the difference resulting in part from four relapses, three toxic deaths, and one presumed unrelated death. These results in the elderly were paralleled by a relatively reduced ability to tolerate therapy. Toxicity was primarily pulmonary, occurring in 39% of patients, two of whom died. With an overall CR rate of 84%, of which 92% are sustained at a median follow-up of 40 months, COPBLAM III represents a highly effective treatment in a sizeable cohort of patients.

UR - http://www.scopus.com/inward/record.url?scp=0023840154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023840154&partnerID=8YFLogxK

U2 - 10.1200/JCO.1988.6.3.425

DO - 10.1200/JCO.1988.6.3.425

M3 - Article

VL - 6

SP - 425

EP - 433

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -

Boyd DB, Coleman M, Papish SW, Topilow A, Kopel SK, Bernhardt B et al. COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma. Journal of Clinical Oncology. 1988 Jan 1;6(3):425-433. https://doi.org/10.1200/JCO.1988.6.3.425